Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I single-blind placebo-controlled dose-ranging study of SRT2379 in LPS-induced inflammation in healthy men
NL-OMON35933Phase 1Not yet recruiting
- Sponsor
- Sirtris Pharmaceuticals
- Start
- Aug 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of SRT2379 in chronic inflammation (4 arms), sponsored by Sirtris Pharmaceuticals. Planned start Aug 2011; status: not yet recruiting.
02
Drugs
SRT2379
03
Conditions
chronic inflammation
Beyond the preview
Go deeper on NL-OMON35933.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON35933.